Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 17/20 | 0.58 |
| ▸ | INSR | P06213 | 15/20 | 0.58 |
| ▸ | IGF1R | P08069 | 15/20 | 0.58 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | ROS1 | P08922 | 1/20 | 0.40 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11916677 | 0.87 | ALK (0.78) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL19288681 | 0.86 | ALK (0.60) | ALKINSRIGF1RPTK2AURKA | |
| SCHEMBL11902141 | 0.83 | ALK (0.77) | ALKINSRIGF1RPTK2AURKA | |
| SCHEMBL11900186 | 0.83 | INSR (0.60) | ALKINSRIGF1RPTK2 | |
| SCHEMBL11900560 | 0.76 | ALK (0.67) | ALKINSRIGF1R | |
| SCHEMBL15207208 | 0.76 | ALK (0.68) | ALKINSRIGF1RROS1EGFR | |
| SCHEMBL15206624 | 0.74 | ALK (0.52) | ALKINSRIGF1RPTK2EGFR | |
| SCHEMBL11900888 | 0.74 | ALK (0.64) | ALKINSRIGF1RROS1EGFR | |
| SCHEMBL11900456 | 0.74 | ALK (0.63) | ALKINSRIGF1RROS1EGFR | |
| SCHEMBL11916592 | 0.73 | ALK (0.87) | ALKINSRIGF1RAURKAROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | ALK 256/4885INSR 941/4885IGF1R 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.